MedTrace Logo

The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting

NCT02271906 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2019-04-30

Study results available
· View outcomes & findings →

Summary

The goal of this clinical research study is to learn if it is tolerable for patients with NSCLC to receive afatinib before surgery. The safety of this drug will also be studied.

Conditions

Interventions

DRUG

BIBW 2992

40 mg by mouth daily for a minimum of 14 days, and until the day of surgery.

Sponsors & Collaborators

Principal Investigators

  • George Simon, MD · M.D. Anderson Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-01
Primary Completion
2017-08-16
Completion
2017-08-16
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02271906 on ClinicalTrials.gov